Patient Information:

• Name: Mark
• Diagnosis: Diabetes (Type 1)
• Date of Birth (D.O.B): April 26, 2002
• Gender: Male
• Country: Republic of Lithuania

Treatment: Interventional therapy, Biotherapy, Physical Therapy, Traditional Chinese Medicine (TCM) at Beijing Puhua International Hospital

Medical History:
Mark, a 17-year-old male from Lithuania, was admitted to Beijing Puhua International Hospital for diabetes management. He had previously received treatments in local and UAE hospitals but achieved suboptimal results. Upon learning about the potential benefits of Chinese biotherapy for diabetes, Mark's family contacted the hospital online and arrived in Beijing at the end of June.

Medical Condition before Interventional therapy and biotherapy for Diabetes:

• Congenital diabetes requiring strict dietary control and daily blood sugar monitoring
• Difficulty concentrating on studies due to his condition

Interventional therapy and biotherapy for Diabetes:
Following admission, Mark underwent relevant examinations, and a comprehensive treatment plan was implemented, consisting of:

• Interventional therapy
• Biotherapy
• Physical Therapy
• Traditional Chinese Medicine (TCM)

The entire treatment course lasted for two weeks.

Medical Condition after Interventional therapy and biotherapy for Diabetes (3 months post-treatment):

• Glycated hemoglobin: 7.5% (pre-treatment: 8.2%)
• C peptide: 0.3 (pre-treatment: < 0.1)

Mark and his family are highly satisfied with the treatment results, as he has been able to reduce the dosage of long-acting insulin. The hospital will continue to monitor Mark's progress and provide guidance on medication adjustments as needed.

Patient Information:

• Name: Faisal Salem
• Diagnosis: Type-2 Diabetes (with Diabetic Nephropathy, Multiple Cerebral Infarction, Right Internal Carotid Artery Occlusion)
• Date of Birth (D.O.B): August 5, 1971
• Gender: Male
• Country: Saudi Arabia

Treatment: Nerve Growth Factor Therapy; medications to enhance peripheral circulation; neuronal nutritional support at Beijing Puhua International Hospital

Medical History:
Faisal was diagnosed with Type II Diabetes Mellitus in 2002, presenting with polydipsia, diuresis, and weight loss. Initially prescribed oral medications, his blood glucose control remained poor due to non-adherence to diabetic diet and exercise therapy. Insulin therapy was initiated, consisting of Aspart 15 Units TID and Glargine 30 Units QD; however, glycemic control was still suboptimal, leading to his admission at Beijing Puhua International Hospital for further management.

Medical Condition before Nerve Growth Factor Therapy:

• Weakness
• Frequent and severe hypoglycemia (4 episodes) despite insulin therapy
• Intolerance to heat with diaphoresis
• Poor dietary control
• Normal urine output but alternating diarrhea and constipation
• Laboratory findings: blood glucose 16.55 mmol/L (high), ALB 33.64 g/L (low), HbA1c 10.30% (high)

Nerve Growth Factor Therapy for Type-2 Diabetes:
Following admission, Faisal received the following treatment regimen:

• Adjustment of hypoglycemic therapy
• Nerve growth factor implantation via intravenous injections
• Traditional Chinese Medicine support

Medical Condition after Nerve Growth Factor Therapy:
Post-Nerve Growth Factor Therapy, Faisal's insulin dosage was gradually reduced due to improved glycemic control. His renal function also demonstrated improvement, with urine protein levels decreasing from 2+ to 1+. Additionally, his HbA1c level decreased from 10.3% to 8%, and blood glucose levels became more stable. Faisal reported better adherence to healthy diets and moderate physical exercise post-treatment. Further improvements are anticipated with continued management.

Patient Information:

• Name: John Clarke
• Diagnosis: Dilated Cardiomyopathy (DCM), Atherosclerosis, Cardiac Failure - Functional Class III, Pacemaker Implant
• Date of Birth (D.O.B): August 1, 1962
• Gender: Male
• Country: Australia

Treatment: Nerve Growth Factor Therapy (NGF+SCT) via intravenous injections, complemented by medical treatments to enhance neural function and promote cerebral blood flow, at Beijing Puhua International Hospital (BPIH)

History:
John Clarke, a 52-year-old male, had been experiencing intermittent chest congestion, dyspnea, and exertional dyspnea for over a decade. His condition deteriorated within the three months preceding admission, with symptoms of cyanosis and edema in his lower limbs. He was admitted to BPIH on September 26th, 2014.

Medical Condition before Nerve Growth Factor Therapy (NGF+SCT) for Dilated Cardiomyopathy:

• Shortness of breath limited walking to less than ten minutes
• Speech difficulties requiring repetition
• Inability to perform everyday activities such as playing with children and engaging in intimate relations
• Frequent dizziness upon lifting his head
• Recommended by local hospital for heart transplantation surgery

Nerve Growth Factor Therapy (NGF+SCT) for Dilated Cardiomyopathy:

• Nerve growth factor implantations via intravenous injections
• Medical treatments to improve neural function and nutrition, promote cerebral blood flow, diabetes management, anticoagulation, and other supportive therapies

Medical Condition after Nerve Growth Factor Therapy (NGF+SCT) for Dilated Cardiomyopathy:

• Significant improvement in general condition
• Able to ambulate one kilometer at a time with ease
• Improved speech and ability to perform light exercise
• Facial appearance healthier without cyanosis
• Diminished dizziness
• Decided against cardiac transplant surgery due to positive outcomes from Nerve Growth Factor therapy for heart failure

Patient Testimonial:
John Clarke is very pleased with the results of his Nerve Growth Factor Therapy, stating that they have far exceeded his expectations.

Patient Information:

• Name: Ahmed Saad Alghamdi
• Diagnosis: Type-2 Diabetes, Peripheral Vascular Disease, Primary Hypertension
• Date of Birth (D.O.B): August 1, 1955
• Gender: Male
• Country: Saudi Arabia

Treatment: Nerve Growth Factor Therapy for Type-2 Diabetes combined with medications to enhance peripheral circulation and neuronal nutritional support at Beijing Puhua International Hospital (BPIH)

Medical History:
Patient Alghamdi Ahmed Saad, a 59-year-old male, was diagnosed with type-2 diabetes approximately 15 years prior to his current admission. Initial symptoms included polydipsia and polyuria. Despite efforts to manage blood sugar levels with oral anti-diabetic medication, control remained unstable, leading to insulin therapy for the following 5 years.

Medical Condition before Nerve Growth Factor Therapy for Type-2 Diabetes:

• Symptoms:
  • Chronic fatigue
  • Joint pain in limbs
  • Paresthesia ("gloved" feelings) in fingers and toes
  • Poor dietary control of diabetes
  • Frequent urination at night
• Physical examination: Diminished peripheral nerve sensitivity
• Blood sugar records:
  • Fasting morning levels around 10 mmol/L (180 mg/dL)
  • Pre-meal levels around 12 mmol/L (216 mg/dL)
  • Labile blood sugar with fluctuations and peaks over 28 mmol/L (497 mg/dL)

Nerve Growth Factor Therapy for Type-2 Diabetes:

• Treatment: Three rounds of Nerve Growth Factor Therapy combined with systemic circulation improvement and neuronal nutritional supplementation

Medical Condition after Nerve Growth Factor Therapy for Type-2 Diabetes:

• Post-treatment blood sugar levels:
  • Significantly lower under usual oral medication (Glimepiride 6mg daily)
  • Reduced Glimepiride dosage to 3mg/day
  • Reduced Glargine (Lantus) insulin dosage from 20u to 18u/day
• Improved blood sugar control maintained at near-normal levels
• Potential future reduction or cessation of oral medication and insulin therapy

Follow-up:

• Email received on July 23, 2015, from patient's wife:
  • Ahmed Alghamdi has stopped taking insulin and all oral diabetic medications
  • Pancreatic amylase level: 38 (indicating endogenous insulin production)
  • C-peptide level: 1.32 (six months post-treatment)